NSE: SHUKRAPHAR · BSE: 524632 · ISIN INE551C01044
Shukra Pharmaceuticals Limited stock analysis
Shukra Pharmaceuticals Limited ranks #361 in the TickerSutra evidence-ranked universe with a score of 66/100 and 95% data confidence. The latest captured fundamentals show ROCE of 36.9%, quarterly sales growth of 336.4% and quarterly profit growth of 1359.2%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 36.9%
- Low debt/equity of 0.06×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
- Extreme base-effect growth requires manual validation
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹20cr | ₹3cr | ₹1cr | 14.0% |
| 2023 | ₹59cr | ₹5cr | ₹4cr | 9.0% |
| 2024 | ₹75cr | ₹19cr | ₹19cr | 26.0% |
| 2025 | ₹33cr | ₹13cr | ₹10cr | 39.0% |
| 2026 | ₹57cr | ₹29cr | ₹22cr | 51.0% |
| TTM | ₹75cr | ₹49cr | ₹36cr | 65.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026.
RoutineShukra Pharmaceuticals Ltd - 524632 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 28 Sept 2026Outcome of AGM
RoutineTrading Window-XBRLNSE · 26 Sept 2026 · Structured filingSHUKRA PHARMACEUTICALS LTD has informed the Exchange about Closure of Trading Window
SHUKRA PHARMACEUTICALS LTD has informed the Exchange about Closure of Trading Window
Open original XBRL sourceNewspaper Publication
RoutineShukra Pharmaceuticals Ltd - 524632 - Corrigendum To Postal Ballot NoticeBSE · 22 Sept 2026Corrigendum to Post Ballot Notice
MANAGEMENT COMMENTARY
Signals from filed documents
Collaborative engagement between the government and industry stakeholders is essential to devise a transparent, predictable, and equitable pricing structure, which incentivizes innovation while ensuring affordable access for all. Shukra Pharmaceuticals advocates for stable and forward-looking pricing policies that promote market predictability, enabling pharmaceutical companies to invest in capacity expansion, resear
Collaborative engagement between the government and industry stakeholders is essential to devise a transparent, predictable, and equitable pricing structure, which incentivizes innovation while ensuring affordable access for all. Shukra Pharmaceuticals advocates for stable and forward-looking pricing policies that promote market predictability, enabling pharmaceutical companies to invest in capacity expansion, resear
We wish that these initiatives, which will lead to a safer healthcare environment for patients, will be followed up in a transparent and rational way. Over the past decade, pharmaceutical companies have entered a difficult period where shareholders, the market and regulators have created significant pressures for change within the industry. The core issues for most drug companies are declining productivity of in-hous
However, in recent years, the industry has encountered several challenges. Regulatory tightening in key export markets, pricing pressures, and supply chain disruptions have collectively moderated growth, bringing the Compound Annual Growth Rate (CAGR) to approximately 7-8%. Domestically, the sector also faces evolving compliance standards, increased competition, and changing healthcare dynamics.
By integrating capabilities across medical consumables, surgical robotics, wound care, diabetes technology, forensic and emergency-response systems, aesthetic medicine, combat medical support, defence, and artificial intelligence, the Group is building a platform for sustained, diversified, and innovation-led growth in the years ahead. KEY ACHIEVEMENTS DURING THE YEAR Financial Year 2025-26 has been a landmark year f
There is no exceptional circumstance for an increase in remuneration. 4) Percentage increase in remuneration indicates annual total compensation increase, as recommended by the Nomination and Remuneration Committee and duly approved by the Board of Directors of the Company. 5) Percentage increase in the median remuneration of all employees in the Financial Year 2025-26: Particulars Remuneration in Rs.
The facility of participation at the AGM through VC/OAVM will be made available to 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…